AlloVir reports Q3 net loss $42.1M; cash $264.1M, advancing Phase 3 posoleucel trials

Kalaris Therapeutics, Inc.

2022-Q3 EPS reported -$1.83

Net loss of $42.1M ($0.50/sh) in Q3 2022 vs $45.5M ($0.72) in Q3 2021.
Cash & securities $264.1M; raised $126.4M net from registered direct offering July 2022.
R&D expenses $30.0M, G&A $12.9M; FY2022 opex guidance $130M-$145M excl. stock comp.
Phase 3 posoleucel trials ongoing; final Phase 2 multi-virus prevention data by year-end.
Topline Phase 2 BK viremia data in kidney transplant patients expected Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kalaris Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-276390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.